Overview

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Status:
Completed

Trial end date:
2016-12-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma who received at least 1 prior chemotherapy regimen.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Research & Development, LLC

Collaborator:

Pharmacyclics LLC.

Treatments:

Everolimus
Sirolimus